青光眼滤过术后创伤愈合的生物学调控

青光眼在全球是仅次于白内障导致视力丧失的主要病因,滤过手术联合应用抗代谢药物降低眼压是控制病情发展的主要手段。但抗代谢药物(MMC,5-FU)产生的毒副作用,使其应用受到限制。近年来众多研究开始转向低副作用、靶向性强、作用强度及作用时间可控的生物学调控,包括靶向细胞因子的各种单克隆抗体、靶向细胞外基质的基质金属蛋白酶、基因调控等,部分制剂已用于临床,显示了良好的应用前景,这无疑是针对青光眼滤过术区创伤愈合调控的理想研究方向。

Biological modulation of wound healing after glaucoma filtering surgery

Glaucoma is one of the leading causes of blindness in the world just second to cataract. Decreasing intraocular pressure by filtering surgery combined with antimetabolites(5-fluorouracil, 5-FU; mitomycin C, MMC)is the main way to control the progress of the disease. However, the side effects of these antimetabolites induced limit their clinical use. In recent years, the researchers have turned to the biological modulation of would healing after filtering surgery in order to obtain biological agents with low side effects, target oriented, effect strength and duration controlling. These biological agents include monoclonal antibodies targeting cytokines, matrix metalloproteinases, and gene therapy and so on. Some of them had been applied clinically and demonstrated good results. This is undoubtedly the ideal research direction to the modulation of wound healing after glaucoma filtering surgery.